<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frank W Drislane, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Garcia, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan A Edlow, MD, FACEP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro A Rabinstein, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Status epilepticus is a relatively common medical and neurologic emergency that requires prompt evaluation and treatment. There are many different status epilepticus syndromes, defined by clinical features and electroencephalogram (EEG) findings. Causes, prognoses, and treatments differ, and optimal evaluation and treatment requires an understanding of both the type of status epilepticus and the underlying cause. Some forms of status epilepticus are associated with an excellent prognosis, while others can have major morbidity or even mortality.</p><p>The clinical features and diagnosis of convulsive status epilepticus in adults are discussed here; treatment is reviewed separately. (See  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults"</a>.)</p><p>Nonconvulsive status epilepticus and the diagnosis and management of status epilepticus in children are also discussed separately. (See  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children"</a> and  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>.)</p><p class="headingAnchor" id="H17916977"><span class="h1">DEFINITION OF STATUS EPILEPTICUS</span><span class="headingEndMark"> — </span>The duration of continuous seizure activity used to define status epilepticus has varied over time. Historically, the International League Against Epilepsy (ILAE) and others defined status epilepticus as a single epileptic seizure of &gt;30 minutes duration or a series of epileptic seizures during which function is not regained between seizures in a 30-minute period<strong> </strong>[<a href="#rid1">1</a>].</p><p>Because of the clinical urgency in treating generalized convulsive status epilepticus (GCSE), however, a 30-minute definition is neither practical nor appropriate in clinical practice. Once seizures have continued for more than a few minutes, treatment should begin without further delay.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Operational definition</strong> – Considering the need for rapid evaluation and intervention in GCSE to avoid cardiovascular morbidity and refractory status, an accepted operational definition of GCSE consists of the following [<a href="#rid2">2-4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥5 minutes of continuous seizures, or</p><p class="bulletIndent2"><span class="glyph">•</span>≥2 discrete seizures between which there is incomplete recovery of consciousness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ILAE definition</strong> – In 2015, the ILAE published a revised conceptual definition of status epilepticus that incorporates two time points, t1 and t2 [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The first, t1, is the time at which ongoing seizure activity should be regarded as abnormally prolonged, unlikely to stop spontaneously, and when treatment for status epilepticus should be started.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The second, t2, is the time after which the ongoing seizure activity poses a significant risk of long-term complications.</p><p></p><p class="bulletIndent1">The ILAE definition is as follows [<a href="#rid5">5</a>]: "Status epilepticus is a condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures (after time point t1). It is a condition that can have long-term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures."</p><p></p><p>For GCSE, the ILAE proposal specifies that t1 and t2 are 5 and 30 minutes, respectively, based on the best available data from animal and clinical studies, and consistent with the operational definition discussed above [<a href="#rid5">5</a>]. The term "convulsive" is defined by the ILAE as designating "episodes of excessive abnormal muscle contractions, usually bilateral, which may be sustained, or interrupted" [<a href="#rid5">5,6</a>]. Convulsive status epilepticus is characterized by the presence of prominent motor symptoms and impairment of consciousness [<a href="#rid5">5</a>]. </p><p>For other types of status epilepticus, the most appropriate time intervals for t1 and t2 have not been well defined and are far more speculative, particularly for nonconvulsive status epilepticus. The ILAE suggests using a t1 and t2 of 10 and &gt;60 minutes for focal status epilepticus with impaired consciousness (often labeled complex partial status epilepticus) and a t1 of 10 to 15 minutes for absence status epilepticus. There are no available data to suggest any particular t2 for absence status epilepticus.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The reported yearly incidence of status epilepticus ranges from 1.3 to 74 cases per 100,000 [<a href="#rid7">7</a>]. Most earlier population-based studies defined status epilepticus using a duration of at least 30 minutes.</p><p>The wide range of reported incidence rates is likely due to differences in case ascertainment and the populations being studied. In addition, some studies have included both convulsive and nonconvulsive status epilepticus (NCSE), while others have excluded NCSE. In a study that included only generalized convulsive status epilepticus, the reported annual incidence rate was 7 cases per 100,000 people [<a href="#rid8">8</a>].</p><p>The incidence of status epilepticus follows a U-shaped distribution, with relatively high incidence rates in children less than one year of age and then rising again in older adults over the age of 60 years [<a href="#rid9">9</a>]. Over a lifetime, up to 10 percent of adults with epilepsy and 20 percent of children with epilepsy will have one or more episodes of status epilepticus [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Most cases of status epilepticus in adults are due to an underlying structural brain lesion or a toxic or metabolic disturbance [<a href="#rid11">11</a>]. If the underlying medical or structural cause is of recent origin (&lt;1 to 2 weeks), status epilepticus is referred to as acute symptomatic or "provoked." Many episodes come from a combination of an earlier lesion (ie, remote symptomatic) and a superimposed new metabolic, infectious, or pharmacologic stressor such as uremia or a medication change.</p><p>Status epilepticus also commonly arises in patients with an established diagnosis of focal or generalized epilepsy. Status epilepticus is occasionally the presenting manifestation of epilepsy [<a href="#rid12">12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common causes</strong> – Common causes of convulsive status epilepticus vary by age. In children, febrile status epilepticus is the most common etiology, accounting for approximately one-third of cases. (See  <a class="medical medical_review" href="/d/html/6222.html" rel="external">"Clinical features and complications of status epilepticus in children", section on 'Epidemiology and etiology'</a>.)</p><p></p><p class="bulletIndent1">In adults, the most common etiologies are acute symptomatic, accounting for approximately half of all cases, followed by remote symptomatic and low antiseizure medication levels in a patient with known epilepsy [<a href="#rid12">12-14</a>]. Examples of some of the more common causes in adults include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute structural brain injury (eg, stroke, head trauma, subarachnoid hemorrhage, cerebral anoxia or hypoxia), infection (encephalitis, meningitis, abscess), or brain tumor. Stroke is the most common, especially in older patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Remote or longstanding structural brain injury (eg, prior head injury or neurosurgery, perinatal cerebral ischemia, cortical malformations, arteriovenous malformations, and low-grade brain tumors).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiseizure medication nonadherence or discontinuation in patients with prior epilepsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Withdrawal syndromes associated with the discontinuation of alcohol, barbiturates, or benzodiazepines.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic abnormalities (eg, hypoglycemia, hepatic encephalopathy, uremia, hyponatremia, hyperglycemia, hypocalcemia, hypomagnesemia) or sepsis. (See  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Acute symptomatic seizures'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of, or overdose with, drugs that lower the seizure threshold, including <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, carbapenems (eg, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>), high-dose <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, quinolone antibiotics, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, tricyclic antidepressants, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="8456" href="/d/drug information/8456.html" rel="external">flumazenil</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, metrizamide, <a class="drug drug_general" data-topicid="9095" href="/d/drug information/9095.html" rel="external">dalfampridine</a>, and, to a lesser extent, phenothiazines, especially at higher doses. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune causes</strong> – An increasingly recognized cause of convulsive seizures and status epilepticus, and especially refractory status epilepticus, is autoimmune encephalitis, which sometimes has an underlying paraneoplastic etiology. Causes include autoantibodies against neuronal proteins, such as the anti-leucine-rich glioma inactivated 1 (LGI1) protein, the N-methyl-D-aspartate (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, and the B1 subunit of the gamma-aminobutyric acid B (GABA-B) receptor; others include multiple sclerosis, adult-onset Rasmussen encephalitis, Hashimoto encephalitis, and lupus vasculitis [<a href="#rid15">15-17</a>].</p><p></p><p class="bulletIndent1">Clinical presentations can range from convulsive status epilepticus to confusional or amnestic states. Autoimmune cases are often more refractory to treatment compared with other causes of status epilepticus but may respond favorably to immunosuppressive therapy [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Immunomodulatory therapy'</a>.)</p><p></p><p class="headingAnchor" id="H567989"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Status epilepticus, like seizures, is categorized electroclinically according to whether seizure activity is focal or generalized. In many cases, however, generalized convulsive status epilepticus (GCSE) cannot be separated easily into cases with a primarily generalized onset versus those with focal onset and secondary generalization. Most GCSE has some evidence of a focal onset or focal lesion [<a href="#rid13">13</a>].</p><p>The distinction between focal and generalized onset has clinical implications: </p><p class="bulletIndent1"><span class="glyph">●</span>In cases with focal onset, a causative lesion must be sought </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In primary generalized epilepsies, certain antiseizure medications (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>) should usually be avoided (see  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Second- or third-line medications'</a> and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Myoclonic status epilepticus'</a>)</p><p></p><p>Both focal and generalized status epilepticus can be further classified according to whether clinical seizure activity is convulsive or nonconvulsive  (<a class="graphic graphic_table graphicRef97140" href="/d/graphic/97140.html" rel="external">table 1</a>). Convulsive forms of status epilepticus are the focus of this topic; nonconvulsive status epilepticus is discussed separately. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a>.)</p><p>Classifying the type of status epilepticus is important because it is a major factor in determining morbidity and, therefore, the aggressiveness of treatment required. For the purposes of this topic, we consider forms of status epilepticus with significant motor (movement) manifestations, including generalized, focal motor, myoclonic, and tonic seizures, to be convulsive.</p><p class="headingAnchor" id="H1217713551"><span class="h1">CLINICAL PRESENTATIONS</span><span class="headingEndMark"> — </span>Patients with convulsive status epilepticus present with characteristic motor manifestations that vary according to the seizure type. </p><p class="headingAnchor" id="H2147238527"><span class="h2">Types of motor manifestations</span><span class="headingEndMark"> — </span>While patients with generalized convulsive status epilepticus (GCSE) have obvious bilateral tonic and/or clonic motor activity and loss of consciousness, patients with focal motor status epilepticus may have jerking movements restricted to one area of the body, usually with preserved consciousness. Myoclonic status epilepticus typically involves much more rapid, but lower amplitude, jerking muscle activity, but with marked variability. Tonic status epilepticus includes slower, more sustained maintenance of a posture, or slow movement. </p><p>Other forms of focal status epilepticus that do not involve motor manifestations, including focal-onset nonconvulsive status epilepticus with altered awareness (previously known as complex partial status epilepticus), are discussed separately. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis", section on 'Electroclinical classification'</a>.)</p><p class="headingAnchor" id="H2161854190"><span class="h2">Generalized convulsive status epilepticus</span><span class="headingEndMark"> — </span>GCSE is the most dramatic form of status epilepticus, with the potential for serious complications, morbidity, and even mortality. GCSE includes both primary generalized and secondarily generalized convulsive seizures, with the latter now officially referred to as focal to bilateral tonic-clonic seizures [<a href="#rid19">19</a>]. There is always impaired consciousness and bilateral tonic stiffening, followed by rhythmic jerking of the limbs (clonus) that is usually symmetric; the initial tonic phase may not be witnessed.</p><p class="headingAnchor" id="H2161854197"><span class="h2">Focal motor status epilepticus</span><span class="headingEndMark"> — </span>Focal status epilepticus has many clinical manifestations, largely depending on the location of the epileptogenic brain area. Focal motor status epilepticus is the most easily recognized. It may have progression along the homunculus of focal jerking activity of a limb (a "Jacksonian march") or widespread but unilateral jerking muscle activity, with or without impaired consciousness.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal lesions</strong> – In almost all cases of focal status epilepticus, there is an associated focal lesion, although the lesion is not always evident on imaging. Examples of causative lesions include heterotopias (clusters of normal neurons in abnormal locations due to disordered neuronal migration), vascular or infectious lesions, and tumors. Occasionally, benign idiopathic (usually genetic) focal epilepsies lead to status epilepticus of the same type. (See  <a class="medical medical_review" href="/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Self-limited epilepsies of childhood'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epilepsia partialis continua</strong> – A particularly refractory focal motor status epilepticus with very prolonged and very regular jerking activity with retained awareness is called epilepsia partialis continua (EPC). EPC can be remarkably persistent, with epileptic focal repetitive jerking activity lasting days, weeks, or even decades [<a href="#rid20">20,21</a>]. Causes include heterotopias, inflammatory or infectious lesions (eg, tuberculosis, syphilis, and toxoplasmosis), vascular lesions, neoplasms, congenital malformations, Rasmussen encephalitis, and hyperosmolar nonketotic hyperglycemia. The jerking is often restricted to one part of the body, does not spread, and is often slower than in most other forms of focal motor status epilepticus.</p><p></p><p class="bulletIndent1">Rasmussen encephalitis, although rare, is a relatively common cause of EPC that occurs in children and adolescents. It is usually manifested by refractory, unremitting focal seizures, progressive cerebral hemiatrophy with contralateral hemiparesis, and progressive cognitive dysfunction. It is often associated with lateralized periodic (epileptiform) discharges on electroencephalogram (EEG). (See  <a class="medical medical_review" href="/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Hemispheric syndromes'</a>.)</p><p></p><p class="bulletIndent1">Hyperosmolar nonketotic hyperglycemia can also cause EPC. Although hyperglycemia and fluid and electrolyte disturbances provide a precipitant for seizures, there is usually an underlying focal cerebral lesion as well [<a href="#rid22">22</a>]. Blood glucose levels can be extremely high, often above 1000 mg/dL. The EPC associated with nonketotic hyperglycemia is usually readily treatable by correcting the metabolic abnormality [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/1792.html" rel="external">"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2161854204"><span class="h2">Myoclonic status epilepticus</span><span class="headingEndMark"> — </span>Myoclonic status epilepticus (MSE) is characterized by frequent, generalized, or focal myoclonic jerks that can be rhythmic or arrhythmic. The EEG often shows rapid epileptiform discharges time-locked to the movements persuasive for an epileptic origin of the myoclonus. Many authors consider myoclonic seizures to become MSE after 30 minutes [<a href="#rid24">24</a>]. MSE has many causes, often divided into epilepsy syndrome-related causes ("true MSE" [<a href="#rid25">25</a>]) and those "symptomatic" of other neurologic or medical illnesses. It has remarkably varied manifestations and occurs in many syndromes, ranging from relatively benign to life-threatening.</p><p>Because the clinical features often fail to distinguish the forms of MSE, the EEG features are often crucial in distinguishing the different etiologies and types of MSE and to guide treatment. (See <a class="local">'Electroencephalography'</a> below.)</p><p>The prognosis of MSE depends on that of the underlying etiology [<a href="#rid21">21</a>]. Following anoxia, it is often fatal; with metabolic encephalopathies, it is often reversible. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic epilepsies</strong> – Many cases of MSE arise in syndromes of primary generalized (genetic) epilepsy (ie, generalized epilepsies with a presumed genetic etiology, without structural lesions in the brain [<a href="#rid26">26</a>]). In the relatively benign MSE syndromes, EEGs have a normal background and patients usually have no developmental or cognitive deficits between seizures. Isolated myoclonus is common, but MSE itself is rare.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relatively benign genetic epilepsy</strong> – The best recognized, relatively benign genetic epilepsy syndrome is juvenile myoclonic epilepsy (JME), in which patients have intermittent myoclonus and myoclonic seizures and sometimes absence seizures and generalized convulsions [<a href="#rid27">27</a>]. The myoclonic jerks of JME tend to be bilateral, especially in the arms, but not particularly rhythmic, and usually correlate with generalized sharp waves, spikes, or polyspikes on the EEG. As with most other genetic generalized epilepsy syndromes, consciousness is usually preserved during the MSE. MSE is often triggered by discontinuing earlier antiseizure medications or from the use of inappropriate antiseizure medications, typically sodium channel-based drugs such as <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, or <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> [<a href="#rid28">28</a>]. Often, the MSE can be interrupted relatively easily by benzodiazepines and other drugs. (See  <a class="medical medical_review" href="/d/html/17192.html" rel="external">"Juvenile myoclonic epilepsy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Less benign genetic epilepsies</strong> – In some less benign epilepsy syndromes, seizures are often refractory and accompanied by severe cognitive impairment. One example is severe myoclonic epilepsy of infancy, also known as Dravet syndrome, a form of epileptic encephalopathy caused by mutations in the SCN1A gene encoding voltage-gated sodium channels, often causing refractory seizures (although MSE itself is rare) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/108278.html" rel="external">"Dravet syndrome: Genetics, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent2">Another example is Lennox-Gastaut syndrome (LGS); patients with LGS typically have severe cognitive impairment and impaired responsiveness, and often have multiple seizure types, especially tonic seizures, but also atonic, absence, myoclonic absence, generalized convulsions, and focal retained awareness seizures. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p></p><p class="bulletIndent2">Other genetic syndromes leading to MSE include myoclonic astatic epilepsy and epilepsy with myoclonic absences. In all these syndromes, MSE is much harder to treat. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic illnesses with encephalopathy</strong> – MSE also occurs in neurologic illnesses in which a concomitant encephalopathy has cognitive deficits, which often causes the patient more impairment than does the seizure activity. One group of such illnesses is termed progressive myoclonus epilepsies, often manifesting with ataxia, action myoclonus, and severe, progressively worsening cognitive deficits and epilepsy [<a href="#rid30">30</a>]. They include storage diseases such as neuronal ceroid lipofuscinosis and Lafora body and Unverricht Lundborg diseases, as well as mitochondrial disorders such as mitochondrial encephalopathy with ragged red fibers (MERRF). This MSE may be interruptible, but the encephalopathy usually progresses. Later-onset myoclonic seizures can also be seen in adults with Down syndrome and Alzheimer disease [<a href="#rid31">31-33</a>]. The EEG often shows a very slow background indicative of a severe encephalopathy. Epileptiform discharges may be multifocal and irregular. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-neurologic illnesses</strong> – MSE may also be symptomatic of illnesses not primarily neurologic, such as infections, inflammatory diseases, and metabolic derangements such as uremic or hepatic encephalopathy, hypercarbic respiratory failure, or multiple medical problems such as a combination of uremia and sepsis (a typical cause) [<a href="#rid34">34</a>]. Drug toxicity may cause myoclonus and myoclonic seizures; antiseizure medications <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> and <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">tiagabine</a> appear to have caused MSE in several cases [<a href="#rid35">35</a>]. An EEG is necessary to confirm status epilepticus in patients with metabolic derangements. The EEG frequently shows a very slow background indicative of a severe encephalopathy, and epileptiform discharges may be multifocal and irregular. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anoxia</strong> – The MSE due to anoxia is the sign of a particularly severe illness, often with a terrible prognosis. It can be extremely difficult to treat, and most patients do poorly even after the MSE resolves, as determined primarily by the effects of the anoxic episode itself. With anoxia, the EEG often shows a very low voltage or even "flat" background with irregular sharp wave discharges, not always correlating with the timing of the myoclonus. An EEG is necessary to confirm status epilepticus in patients with myoclonus after anoxia (See  <a class="medical medical_review" href="/d/html/4833.html" rel="external">"Hypoxic-ischemic brain injury in adults: Evaluation and prognosis"</a> and <a class="local">'Electroencephalography'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent, nonepileptic myoclonus</strong> – Not all episodes of persistent myoclonus are epileptic in origin; many are better labeled "status myoclonicus" rather than truly epileptic. They include prolonged, continuous, but frequently nonrhythmic, myoclonic jerking, usually of large amplitude, often involving the face, trunk, and limbs, but sometimes multifocal or asynchronous. The cause is usually an acute, severe encephalopathy, particularly anoxia [<a href="#rid21">21,31</a>], although metabolic disturbances are also common [<a href="#rid21">21</a>]. Most patients are comatose [<a href="#rid31">31</a>]. The EEG typically shows widespread slowing indicative of an encephalopathy (and in the case of anoxia, a very low voltage or even "flat" background), and the myoclonic jerks do not correlate with spikes or sharp waves. (See <a class="local">'Electroencephalography'</a> below.) </p><p></p><p class="headingAnchor" id="H2161854211"><span class="h2">Tonic status epilepticus</span><span class="headingEndMark"> — </span>Tonic status epilepticus (TSE) is rare in adults. It consists of maintenance of a tonic posture, particularly of axial musculature, rather than frank convulsions [<a href="#rid36">36</a>]. It usually occurs in children with many different seizure types, particularly those who have major neurologic and cognitive deficits from birth or early childhood, such as Lennox-Gastaut syndrome. The EEG may show widespread fast activity or very rapid spikes but may also include periods of background suppression or attenuation. TSE can be difficult to abort with antiseizure medications [<a href="#rid37">37</a>]. Occasionally, benzodiazepines may exacerbate TSE [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p class="headingAnchor" id="H517580325"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H7"><span class="h2">Electroencephalography</span><span class="headingEndMark"> — </span>An urgent portable electroencephalogram (EEG) should be obtained if there is uncertainty regarding the presence of status epilepticus. For patients with status epilepticus whose seizure has appeared to stop clinically but the patient's mental status is not clearly improving clinically or returning to baseline, an EEG should be done quickly to look for nonconvulsive seizures. An EEG may not be necessary for patients with known epilepsy who return to baseline after an episode of status epilepticus. </p><p>Continuous EEG monitoring is necessary for the management of refractory status epilepticus. (See  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Continuous EEG monitoring'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EEG in generalized convulsive status epilepticus</strong> – During generalized convulsive status epilepticus (GCSE), the EEG recording is often obscured by muscle and movement artifacts, but it may show continuous spike and wave activity indicative of generalized seizure activity. In some cases of GCSE, a focal onset is evident on EEG, especially early in the episode, and this can help to focus the evaluation on an underlying focal cause. Once convulsions have ceased, EEG is crucial in determining whether status epilepticus has truly ended, or whether there is continuing seizure activity without convulsions, especially if the patient is not rapidly waking up after movements cease. (See <a class="local">'Generalized convulsive status epilepticus'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EEG in focal motor status epilepticus</strong> – In many cases of focal motor status epilepticus, EEG evidence of seizure activity is subtle or absent [<a href="#rid40">40</a>]. This is generally thought due to a small or deep seizure focus or orientation of the seizure discharges such that they are not evident on surface, scalp EEGs. The seizures of focal status epilepticus can also be intermittent and thereby absent on a short EEG recording. (See <a class="local">'Focal motor status epilepticus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EEG in unresponsive patients</strong> – Certain EEG patterns in unresponsive patients are diagnostic of status epilepticus, including patterns that show discrete or merged seizures with temporal and spatial evolution. The meaning of other patterns, such as lateralized periodic discharges (LPDs; previously referred to as periodic lateralized epileptiform discharges [PLEDS])  (<a class="graphic graphic_waveform graphicRef94774" href="/d/graphic/94774.html" rel="external">waveform 1</a>), remains controversial, although aggressive pharmacologic treatment in a patient whose EEG shows only LPDs without evolution and whose examination shows no clinical seizures should generally be avoided [<a href="#rid41">41</a>]. Continuous EEG recordings may be helpful if the initial study is not diagnostic. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis", section on 'Electroencephalography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EEG in myoclonic status epilepticus</strong> – In myoclonic status epilepticus (MSE), EEG features can help to distinguish among the different etiologic groups, in turn helping to direct management. The "primary" or "idiopathic" (usually genetic) generalized myoclonic epilepsy syndromes, especially the benign syndromes, often show generalized polyspikes on a relatively normal background. In the other, more severe myoclonic epilepsy syndromes, there may be background slowing and less rhythmic and broader spikes, sometimes with periodic discharges. Cases with acute or remote symptomatic causes may show focal slowing; many show more widespread background slowing, indicative of an encephalopathy. (See <a class="local">'Myoclonic status epilepticus'</a> above.)</p><p></p><p class="bulletIndent1">The background EEG rhythm in MSE generally correlates better with prognosis than do the clinical manifestations. Cases with the particularly ominous MSE due to anoxia may show a very disturbed, nearly flat background EEG, indicative of an extremely severe encephalopathy and predictive of a poor prognosis. </p><p></p><p class="headingAnchor" id="H966515"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>A neuroimaging study is essential when status epilepticus is the first presentation of epilepsy, when evaluating a patient with a suspected focal onset of status epilepticus, and when recovery from status epilepticus does not follow the expected course. A noncontrast computed tomography (CT) scan of the head may be performed in the emergency department setting (eg, to look for a cerebral hemorrhage or major structural lesion such as a tumor or large stroke), but magnetic resonance imaging (MRI) has superior yield for determining the underlying etiology. </p><p>Once the patient is stabilized, a head CT may be obtained, but MRI is preferred (if available) as the best test to show the structural lesions that may cause or precipitate status epilepticus. However, MRI is not necessary to diagnose status epilepticus and cannot be performed until a patient is stabilized and seizures have been controlled. </p><p>The neuroimaging evaluation of epilepsy is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2228.html" rel="external">"Neuroimaging in the evaluation of seizures and epilepsy"</a>.) </p><p>Aside from underlying structural lesions that may identify the underlying cause of seizures, MRI can show abnormalities due to recent prolonged seizures themselves; these are often reversible. Examples include areas of increased signal intensity on fluid attenuated inversion recovery, T2, or diffusion-weighted images; patchy contrast enhancement; and increased blood flow on perfusion-weighted imaging  (<a class="graphic graphic_table graphicRef59643" href="/d/graphic/59643.html" rel="external">table 2</a>). These findings are thought to represent seizure-induced cellular edema. They are most often seen in cortical and limbic structures, particularly the hippocampus or other deep structures such as the pulvinar. Many are reversible but may last for weeks or longer [<a href="#rid42">42</a>], especially if seizures are prolonged; they ultimately resolve or evolve into focal atrophy and sclerosis. It is not always easy to tell the difference between seizure-related findings and an underlying causative lesion, and repeat imaging may be necessary [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/2234.html" rel="external">"Magnetic resonance imaging changes related to acute seizure activity", section on 'Local peri-ictal MRI findings'</a>.)</p><p class="headingAnchor" id="H568112"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>GCSE is a clinical diagnosis, confirmed in most cases by the presence on examination of sustained and generalized tonic and/or rhythmic clonic motor activity lasting for longer than five minutes or repetitive convulsive seizures without a return to baseline consciousness between seizures. </p><p>Although the diagnosis of GCSE is usually obvious, a detailed neurologic examination is important in making the diagnosis of more subtle or focal forms of status epilepticus. (See <a class="local">'Clinical presentations'</a> above.)</p><p>Particularly important are assessment of the level of consciousness, observation for automatic movements or myoclonus, and any asymmetric features on examination that may indicate a focal structural lesion. (See  <a class="medical medical_review" href="/d/html/5095.html" rel="external">"The detailed neurologic examination in adults"</a> and  <a class="medical medical_review" href="/d/html/5104.html" rel="external">"Stupor and coma in adults", section on 'Neurologic examination'</a>.)</p><p>Clinically obvious status epilepticus should be treated immediately; there is no need to wait for an EEG. An EEG is critical in the diagnosis of more subtle forms of status epilepticus, for distinguishing myoclonic status epilepticus from nonepileptic myoclonus, and in the aftermath of generalized convulsive status epilepticus to exclude ongoing nonconvulsive seizures. (See <a class="local">'Electroencephalography'</a> above and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a>.)</p><p class="headingAnchor" id="H17913476"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Few other conditions appear similar to generalized convulsive status epilepticus (GCSE). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Encephalopathies</strong> – Many other conditions, mostly various causes of encephalopathies (eg, hypercarbic respiratory failure, other metabolic disorders), can cause unresponsiveness and abnormal movements; examples include irregular movements consistent with myoclonus, or regular movements consistent with inducible clonus, tremors, or shivering. These movements may be hard to distinguish from nonconvulsive status epilepticus, or even convulsive status epilepticus. The electroencephalogram (EEG) usually shows a very slow background indicative of a severe encephalopathy without epileptiform discharges; however, it may also show rhythmic or periodic discharges that require monitoring over time in order to distinguish them from seizure-related patterns. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis", section on 'Electroencephalography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychogenic nonepileptic seizures (PNES) and psychogenic status epilepticus</strong> – Although relatively uncommon, psychogenic status epilepticus should be considered in situations where there are bilateral motor movements with at least some preservation of responsiveness. Some frontal-onset seizures can also cause bilateral movements with preserved alertness (and memory), but consciousness is not preserved in GCSE. </p><p></p><p class="bulletIndent1">Video and EEG monitoring are the best way to establish the correct diagnosis. Not all seizures show up on an EEG, but prolonged episodes of impaired awareness or behavior without any changes on EEG are unlikely to represent true status epilepticus (remembering that the EEG often remains normal during focal aware seizures as well, including focal aware status epilepticus).</p><p></p><p class="bulletIndent1">Psychogenic status epilepticus is important to recognize, because iatrogenic injury can occur through over-treatment with benzodiazepines. PNES and psychogenic status epilepticus are discussed separately. (See  <a class="medical medical_review" href="/d/html/2227.html" rel="external">"Psychogenic nonepileptic seizures: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Movement disorders</strong> – Some movement disorders occasionally mimic status epilepticus. An EEG at the time of the movements or examination by an experienced clinician will differentiate them from status epilepticus. Tremors and dystonic movements do not usually cause diminished responsiveness. However, dystonic posturing may occur with paroxysmal sympathetic hyperactivity in unresponsive patients with severe traumatic brain injury or intracranial hemorrhage. (See  <a class="medical medical_review" href="/d/html/122115.html" rel="external">"Paroxysmal sympathetic hyperactivity", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basilar territory stroke</strong> – Another very uncommon condition that can mimic (or trigger) seizures or status epilepticus is acute basilar artery stroke, with pontine, midbrain, or thalamic infarctions, or combinations of these, presenting with seizure-like motor activity [<a href="#rid44">44-49</a>]. In most reported cases, an EEG was not performed at the time of the convulsive movements, so their relationship to seizures was unknown. Some patients with bilateral paramedian thalamic or midbrain infarctions (or both) had seizures or status epilepticus (convulsive or nonconvulsive) confirmed by EEG [<a href="#rid45">45,49</a>]. Abnormal eye movements (eg, nystagmus, limited vertical gaze, ocular bobbing) or pupillary findings (eg, miosis as part of a Horner syndrome) were present in most of these cases. Basilar stroke is confirmed by neuroimaging, preferably with brain MRI, which is more sensitive than CT for detection of acute ischemic stroke; many brainstem strokes are too small to be detected by CT scan. (See  <a class="medical medical_review" href="/d/html/1102.html" rel="external">"Posterior circulation cerebrovascular syndromes", section on 'Basilar artery'</a>.)</p><p></p><p class="headingAnchor" id="H1711530880"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Status epilepticus is a medical and neurologic emergency that requires prompt evaluation and treatment. The treatment of convulsive status epilepticus is summarized in the algorithm  (<a class="graphic graphic_algorithm graphicRef74649" href="/d/graphic/74649.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults"</a>.)</p><p class="headingAnchor" id="H302039813"><span class="h1">COMPLICATIONS AND OUTCOME</span></p><p class="headingAnchor" id="H3502530920"><span class="h2">Generalized convulsive status epilepticus</span><span class="headingEndMark"> — </span>The prognosis of status epilepticus depends most strongly on the underlying etiology, but there is some evidence that status epilepticus is independently associated with mortality and neurologic sequelae. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – The mortality rate for adults who present with a first episode of generalized convulsive status epilepticus (GCSE) is roughly 16 to 20 percent [<a href="#rid50">50-54</a>]. Estimates vary widely, mainly as a function of the underlying etiology and whether status epilepticus following cerebral anoxia is included in the study [<a href="#rid9">9,10,52,53</a>]. The mortality for status epilepticus after anoxia ranges from 69 to 81 percent [<a href="#rid54">54-56</a>]. While etiology is the most important predictor of outcome, older age, medical comorbidity, and high initial APACHE-II scores (a prognostic scoring system for intensive care unit patients based on underlying disease, chronic conditions, and physiologic variables) are also independent risk factors for mortality [<a href="#rid53">53,57-60</a>]. (See  <a class="medical medical_review" href="/d/html/1655.html" rel="external">"Predictive scoring systems in the intensive care unit", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of underlying etiology</strong> – Many of the underlying causes of GCSE (see <a class="local">'Etiology'</a> above) are associated with significant morbidity and mortality, even in the absence of seizures. In one series, 89 percent of deaths in patients with status epilepticus were attributed to the underlying etiology [<a href="#rid61">61</a>]. Another study found that acute symptomatic status epilepticus is associated with a sixfold increased risk of mortality compared with status epilepticus arising from chronic epilepsy [<a href="#rid62">62</a>]. Mortality is also lower in individuals who have previously survived an episode of status epilepticus (4.8 versus 15.6 percent in one study), again suggesting that the underlying etiology is a major determinant of outcome in status epilepticus [<a href="#rid58">58,63</a>]. In one report, patients who received mechanical ventilation had a threefold increase in mortality [<a href="#rid53">53</a>], likely due in large part to more refractory status epilepticus, underlying etiology, and medical comorbidity rather than an independent effect of ventilatory support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic consequences</strong> – Systemic consequences of GCSE include cardiac arrhythmias, hypoventilation and hypoxia, fever, and leukocytosis [<a href="#rid64">64</a>]. Aspiration pneumonitis, neurogenic pulmonary edema, and respiratory failure may complicate status epilepticus. Cardiac injury due to massive release of catecholamines may also contribute to morbidity [<a href="#rid65">65-67</a>]. (See  <a class="medical medical_review" href="/d/html/1093.html" rel="external">"Complications of stroke: An overview", section on 'Neurogenic cardiac damage'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic consequences</strong> – Physiologically, there appear to be deleterious neurologic effects of status epilepticus that worsen after approximately 30 minutes in humans, at least for GCSE, and similar derangements may occur after nonconvulsive status epilepticus [<a href="#rid68">68</a>]. Longer seizure duration and status epilepticus in the setting of acute neurologic insult are risk factors for long-term neurologic disability. In some series, 10 to 50 percent of survivors are left with disabling neurologic deficits, particularly after prolonged refractory status epilepticus [<a href="#rid62">62,69,70</a>]. (See  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Outcomes'</a>.)</p><p></p><p class="bulletIndent1">Status epilepticus may also be epileptogenic. Approximately 10 percent of chronic epilepsy presents with status epilepticus [<a href="#rid71">71</a>]. Conversely, approximately 40 percent of patients with a first episode of status epilepticus develop subsequent epilepsy [<a href="#rid72">72</a>], four times the rate following a single acute symptomatic seizure. It could be, however, that patients more likely to have epilepsy in the future may begin with more severe seizures at the onset, ie, status epilepticus may represent a marker for a more severe epileptic process that has already begun [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Adult survivors of status epilepticus are at significant risk for recurrent seizures and status epilepticus [<a href="#rid10">10</a>]. In a population-based study that followed patients for ten years, status epilepticus recurred in approximately one-third of patients [<a href="#rid72">72</a>]. When patients with progressive neurologic disease were excluded, the risk was 25 percent and was similar among other etiologic subgroups. Female sex and a failure to respond to the first drug administered for status epilepticus were risk factors for recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive outcomes</strong> – A number of studies of the cognitive consequences of status epilepticus have found minimal neuropsychologic morbidity [<a href="#rid73">73,74</a>], but most of these studies were pediatric and retrospective. Comprehensive neuropsychologic evaluations before and after status epilepticus are seldom available. It is difficult to control for many variables, and it is also often unclear whether the underlying illness or status epilepticus itself causes morbidity. Many neurologic deficits fluctuate due to the underlying illness, and patients with progressive illness will worsen, irrespective of any additional morbidity due to status epilepticus. Furthermore, it is difficult to control for many variables that affect cognition, including the influence of antiseizure medications. Medications, doses, serum levels, and drug interactions may change frequently in patients with refractory epilepsy, including at the time of testing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathology</strong> – Pathologic studies of the effects of status epilepticus in humans are scarce, in part because fatal cases are often associated with acute, severe brain-injuring illnesses such as ischemic stroke, hemorrhage, and encephalitis, all of which may cause damage independently.</p><p></p><p class="bulletIndent1">Experimentally, neuronal death can occur under certain circumstances after as little as 30 to 60 minutes of continuous seizure activity [<a href="#rid75">75,76</a>]. One pathologic correlate of this phenomenon, cortical laminar necrosis, may also be seen on brain magnetic resonance imaging (MRI) as a persistent, high-intensity lesion on T1 or diffusion-weighted images, which follows the gyral anatomy of the cerebral cortex [<a href="#rid77">77,78</a>]. This may have a clinical correlate in the increased neurologic morbidity that follows status epilepticus of longer duration, even after controlling for the effects of etiology [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H1439959042"><span class="h2">Focal motor status epilepticus</span><span class="headingEndMark"> — </span>The long-term prognosis of focal motor status epilepticus depends on the prognosis of the underlying lesion. Long-term morbidity in terms of weakness, sensory and visual loss, and language dysfunction can be substantial, and many patients have severe cognitive problems [<a href="#rid80">80</a>]. In one series, nearly half the patients died over a follow-up averaging three years, usually because of the underlying causative lesion [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H600844093"><span class="h2">Myoclonic status epilepticus</span><span class="headingEndMark"> — </span>As with treatment, the prognosis of myoclonic status epilepticus (MSE) is strongly dependent upon the form of MSE. The more benign primary generalized epilepsy syndromes (such as juvenile myoclonic epilepsy) seldom lead to MSE. Rare occurrences of MSE caused by a primary generalized epilepsy syndrome typically respond well to treatment and resolve with no residual morbidity. </p><p>In other myoclonic epilepsy syndromes in which encephalopathy is more prominent than myoclonus interictally, status epilepticus is typically more refractory to antiseizure medications. The MSE can usually be brought under control, but underlying neurologic deficits may persist or worsen. The same is true for MSE in chronic or progressive neurologic illnesses, such as mitochondrial encephalopathies or storage diseases. </p><p>MSE in the setting of a new, acute encephalopathy, whether due to infection or metabolic disturbance, has the prognosis of the underlying encephalopathy. Patients with MSE due to multiple medical problems, such as a combination of uremia and sepsis, tend to have poor outcomes. If the encephalopathy can be treated successfully, however, the MSE is likely to resolve without major morbidity from the seizures. </p><p>The prognosis is poorest for patients with MSE due to an acute new illness, particularly when there has been a period of anoxia [<a href="#rid81">81-83</a>]. In such cases, the prognosis is determined by the anoxia, rather than by the seizures [<a href="#rid84">84,85</a>]. Rarely, patients recover from multifocal and irregular myoclonus after anoxia [<a href="#rid86">86,87</a>]. In a review of several studies including 134 cases of post-anoxic MSE, 89 percent of patients died, 8 percent remained in a state of unresponsive wakefulness (previously referred to as a persistent vegetative state), and 3 percent survived; only two had a good recovery [<a href="#rid88">88</a>]. The prognosis for MSE due to anoxia may be improved somewhat by targeted temperature management, but data are limited [<a href="#rid89">89</a>]. Patients with MSE due to multiple medical problems, such as a combination of uremia and sepsis, also tend to have poor outcomes. (See  <a class="medical medical_review" href="/d/html/4833.html" rel="external">"Hypoxic-ischemic brain injury in adults: Evaluation and prognosis"</a>.)</p><p class="headingAnchor" id="H982588880"><span class="h2">Refractory status epilepticus</span><span class="headingEndMark"> — </span>Refractory status epilepticus is defined as status epilepticus that does not cease with administration of two antiseizure medications (administered in appropriate and adequate doses; usually an intravenous benzodiazepine, followed, if necessary, by a longer-acting antiseizure medication). </p><p>Super-refractory status epilepticus is defined as status epilepticus persisting or recurring after at least 24 hours of highly sedating antiseizure drugs (often referred to as anesthetics), usually <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a>, <a class="drug drug_general" data-topicid="9754" href="/d/drug information/9754.html" rel="external">pentobarbital</a>, or <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>. (See  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Definition and etiology'</a>.) </p><p>The outcome of refractory status epilepticus is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Outcomes'</a>.)</p><p class="headingAnchor" id="H668225541"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113971.html" rel="external">"Society guideline links: Seizures and epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H24965573"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16568.html" rel="external">"Patient education: Epilepsy in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Generalized convulsive status epilepticus (GCSE) is operationally defined as ≥5 minutes of continuous seizure activity with prominent motor activity, usually bilateral, or more than one seizure without recovery in between. This establishes the critical point at which treatment must be initiated in order to avoid serious morbidity. (See <a class="local">'Definition of status epilepticus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The incidence of status epilepticus follows a bimodal age distribution, with peak rates in children less than one year of age and adults over the age of 60 years. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Etiologies of status epilepticus include acute brain injury or infection, noncompliance with antiseizure medication treatment, drug or alcohol withdrawal syndromes, and metabolic disturbances, among others. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Classifying the type of status epilepticus is important because it is a major factor in determining morbidity and, therefore, the aggressiveness of treatment required. The four major forms of convulsive status epilepticus are generalized convulsive, focal motor, myoclonic, and tonic. Various forms of nonconvulsive status epilepticus are discussed separately. (See <a class="local">'Classification'</a> above and  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients with convulsive status epilepticus present with characteristic motor manifestations that vary according to the seizure type. While patients with generalized convulsive status have obvious bilateral tonic followed by clonic motor activity and loss of consciousness, patients with focal motor status may have jerking or other movements limited to one limb and many retain awareness. (See <a class="local">'Clinical presentations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – GCSE is a clinical diagnosis, confirmed in most cases by the presence on exam of sustained and/or rhythmic generalized or focal tonic and/or clonic motor activity lasting for ≥5 minutes. Electroencephalography (EEG) is often necessary in the aftermath of GCSE to exclude ongoing nonconvulsive seizures and is mandatory for managing prolonged and refractory status epilepticus. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Electroencephalography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – The prognosis of status epilepticus depends most strongly on the underlying etiology, but there is some evidence that status epilepticus is independently associated with mortality and neurologic sequelae. (See <a class="local">'Complications and outcome'</a> above.)</p><p></p><p class="headingAnchor" id="H1237522244"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mark M Stecker, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993; 34:592.</a></li><li><a class="nounderline abstract_t">Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120.</a></li><li><a class="nounderline abstract_t">Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17:3.</a></li><li><a class="nounderline abstract_t">Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006; 5:246.</a></li><li><a class="nounderline abstract_t">Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56:1515.</a></li><li><a class="nounderline abstract_t">Blume WT, Lüders HO, Mizrahi E, et al. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001; 42:1212.</a></li><li><a class="nounderline abstract_t">Leitinger M, Trinka E, Zimmermann G, et al. Epidemiology of status epilepticus in adults: Apples, pears, and oranges - A critical review. Epilepsy Behav 2020; 103:106720.</a></li><li><a class="nounderline abstract_t">Wu YW, Shek DW, Garcia PA, et al. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002; 58:1070.</a></li><li><a class="nounderline abstract_t">Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004; 11:800.</a></li><li><a class="nounderline abstract_t">Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40:9.</a></li><li><a class="nounderline abstract_t">Barry E, Hauser WA. Status epilepticus: the interaction of epilepsy and acute brain disease. Neurology 1993; 43:1473.</a></li><li><a class="nounderline abstract_t">Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998; 50:735.</a></li><li><a class="nounderline abstract_t">DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46:1029.</a></li><li><a class="nounderline abstract_t">Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000; 55:693.</a></li><li><a class="nounderline abstract_t">Spatola M, Novy J, Du Pasquier R, et al. Status epilepticus of inflammatory etiology: a cohort study. Neurology 2015; 85:464.</a></li><li><a class="nounderline abstract_t">Geis C, Planagumà J, Carreño M, et al. Autoimmune seizures and epilepsy. J Clin Invest 2019; 129:926.</a></li><li><a class="nounderline abstract_t">Suga H, Yanagida A, Kanazawa N, et al. Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features. Epilepsia 2021; 62:2719.</a></li><li><a class="nounderline abstract_t">Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy. Epilepsy Behav 2015; 47:17.</a></li><li><a class="nounderline abstract_t">Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58:522.</a></li><li><a class="nounderline abstract_t">Juul-Jensen P, Denny-Brown D. Epilepsia partialis continua. Arch Neurol 1966; 15:563.</a></li><li><a class="nounderline abstract_t">Thomas JE, Reagan TJ, Klass DW. Epilepsia partialis continua. A review of 32 cases. Arch Neurol 1977; 34:266.</a></li><li><a class="nounderline abstract_t">Singh BM, Strobos RJ. Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients. Ann Neurol 1980; 8:155.</a></li><li><a class="nounderline abstract_t">Singh BM, Gupta DR, Strobos RJ. Nonketotic hyperglycemia and epilepsia partialis continua. Arch Neurol 1973; 29:187.</a></li><li class="breakAll">Serafini A, Gerard EE, Schuele S. Myoclonic status epilepticus. In: Status epilepticus: A clinical perspective, 2nd ed, Drislane FW, Kaplan PW (Eds), Humana Press, Cham 2017. p.139.</li><li><a class="nounderline abstract_t">Gastaut H. Classification of status epilepticus. Adv Neurol 1983; 34:15.</a></li><li><a class="nounderline abstract_t">Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.</a></li><li><a class="nounderline abstract_t">Asconapé J, Penry JK. Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 1984; 25:108.</a></li><li><a class="nounderline abstract_t">Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain 2006; 129:1281.</a></li><li class="breakAll">Ohtahara S, Ohtsuka Y. Myoclonic status epilepticus. In: Epilepsy: A Comprehensive Textbook, Engel J Jr, Pedley TA (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.725.</li><li><a class="nounderline abstract_t">Kälviäinen R. Progressive Myoclonus Epilepsies. Semin Neurol 2015; 35:293.</a></li><li><a class="nounderline abstract_t">De Simone R, Puig XS, Gélisse P, et al. Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome. Seizure 2010; 19:383.</a></li><li><a class="nounderline abstract_t">Vignoli A, Zambrelli E, Chiesa V, et al. Epilepsy in adult patients with Down syndrome: a clinical-video EEG study. Epileptic Disord 2011; 13:125.</a></li><li><a class="nounderline abstract_t">Aller-Alvarez JS, Menéndez-González M, Ribacoba-Montero R, et al. Myoclonic epilepsy in Down syndrome and Alzheimer disease. Neurologia 2017; 32:69.</a></li><li><a class="nounderline abstract_t">Jumao-as A, Brenner RP. Myoclonic status epilepticus: a clinical and electroencephalographic study. Neurology 1990; 40:1199.</a></li><li><a class="nounderline abstract_t">Knake S, Klein KM, Hattemer K, et al. Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. Epilepsy Behav 2007; 11:471.</a></li><li><a class="nounderline abstract_t">GASTAUT H, ROGER J, OUAHCHI S, et al. An electro-clinical study of generalized epileptic seizures of tonic expression. Epilepsia 1963; 4:15.</a></li><li><a class="nounderline abstract_t">Somerville ER, Bruni J. Tonic status epilepticus presenting as confusional state. Ann Neurol 1983; 13:549.</a></li><li><a class="nounderline abstract_t">Alvarez V, Drislane FW. Is Favorable Outcome Possible After Prolonged Refractory Status Epilepticus? J Clin Neurophysiol 2016; 33:32.</a></li><li><a class="nounderline abstract_t">Matthews E, Alkhachroum A, Massad N, et al. New-onset super-refractory status epilepticus: A case series of 26 patients. Neurology 2020; 95:e2280.</a></li><li><a class="nounderline abstract_t">Devinsky O, Kelley K, Porter RJ, Theodore WH. Clinical and electroencephalographic features of simple partial seizures. Neurology 1988; 38:1347.</a></li><li><a class="nounderline abstract_t">Reiher J, Rivest J, Grand'Maison F, Leduc CP. Periodic lateralized epileptiform discharges with transitional rhythmic discharges: association with seizures. Electroencephalogr Clin Neurophysiol 1991; 78:12.</a></li><li><a class="nounderline abstract_t">Boyd JG, Taylor S, Rossiter JP, et al. New-onset refractory status epilepticus with restricted DWI and neuronophagia in the pulvinar. Neurology 2010; 74:1003.</a></li><li><a class="nounderline abstract_t">Cianfoni A, Caulo M, Cerase A, et al. Seizure-induced brain lesions: a wide spectrum of variably reversible MRI abnormalities. Eur J Radiol 2013; 82:1964.</a></li><li><a class="nounderline abstract_t">Ropper AH. 'Convulsions' in basilar artery occlusion. Neurology 1988; 38:1500.</a></li><li><a class="nounderline abstract_t">Lin SF, Lin TC, Hu HH, Chen CI. Bilateral Paramedian Thalamic Infarction Presenting as Status Epilepticus: A Case Report and Review of the Literatures. Acta Neurol Taiwan 2015; 24:125.</a></li><li><a class="nounderline abstract_t">Organek N, Milano N, Donohue M, et al. Significant period between presentation and diagnosis in basilar artery occlusion: five cases and the lessons learned. Stroke 2015; 46:e79.</a></li><li><a class="nounderline abstract_t">Yamashiro K, Furuya T, Noda K, et al. Convulsive movements in bilateral paramedian thalamic and midbrain infarction. Case Rep Neurol 2011; 3:289.</a></li><li><a class="nounderline abstract_t">Conte WL, Gill CE, Biller J. Top of the Basilar Syndrome Presenting With Convulsions. JAMA Neurol 2017; 74:248.</a></li><li><a class="nounderline abstract_t">Mader EC Jr, Losada V, Baity JC, et al. Stroke-Onset Seizures During Midbrain Infarction in a Patient With Top of the Basilar Syndrome. J Investig Med High Impact Case Rep 2020; 8:2324709620940497.</a></li><li><a class="nounderline abstract_t">Logroscino G, Hesdorffer DC, Cascino G, et al. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997; 38:1344.</a></li><li><a class="nounderline abstract_t">Neligan A, Noyce AJ, Gosavi TD, et al. Change in Mortality of Generalized Convulsive Status Epilepticus in High-Income Countries Over Time: A Systematic Review and Meta-analysis. JAMA Neurol 2019; 76:897.</a></li><li><a class="nounderline abstract_t">Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med 1980; 69:657.</a></li><li><a class="nounderline abstract_t">Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology 2007; 69:886.</a></li><li><a class="nounderline abstract_t">Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35:27.</a></li><li><a class="nounderline abstract_t">DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12:316.</a></li><li><a class="nounderline abstract_t">Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43:483.</a></li><li><a class="nounderline abstract_t">Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380.</a></li><li><a class="nounderline abstract_t">Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006; 77:611.</a></li><li><a class="nounderline abstract_t">Canouï-Poitrine F, Bastuji-Garin S, Alonso E, et al. Risk and prognostic factors of status epilepticus in the elderly: a case-control study. Epilepsia 2011; 52:1849.</a></li><li><a class="nounderline abstract_t">Alvarez V, Januel JM, Burnand B, Rossetti AO. Role of comorbidities in outcome prediction after status epilepticus. Epilepsia 2012; 53:e89.</a></li><li class="breakAll">Shorvon S. Prognosis and outcome of status epilepticus. In: Status epilepticus: its clinical features and treatment in children and adults, Shorvon S (Ed), Cambridge University Press, Cambridge 1999. p.293.</li><li><a class="nounderline abstract_t">Claassen J, Lokin JK, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58:139.</a></li><li><a class="nounderline abstract_t">Hawkes MA, English SW, Mandrekar JN, et al. Causes of Death in Status Epilepticus. Crit Care Med 2019; 47:1226.</a></li><li><a class="nounderline abstract_t">Hocker S. Systemic complications of status epilepticus--An update. Epilepsy Behav 2015; 49:83.</a></li><li><a class="nounderline abstract_t">Manno EM, Pfeifer EA, Cascino GD, et al. Cardiac pathology in status epilepticus. Ann Neurol 2005; 58:954.</a></li><li><a class="nounderline abstract_t">Simon RP, Aminoff MJ, Benowitz NL. Changes in plasma catecholamines after tonic-clonic seizures. Neurology 1984; 34:255.</a></li><li><a class="nounderline abstract_t">Hocker S, Prasad A, Rabinstein AA. Cardiac injury in refractory status epilepticus. Epilepsia 2013; 54:518.</a></li><li><a class="nounderline abstract_t">Lothman E. The biochemical basis and pathophysiology of status epilepticus. Neurology 1990; 40:13.</a></li><li><a class="nounderline abstract_t">Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol 2009; 66:1505.</a></li><li><a class="nounderline abstract_t">Legriel S, Azoulay E, Resche-Rigon M, et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010; 38:2295.</a></li><li class="breakAll">Shinnar S, Babb TL. Long-term sequelae of status epilepticus. In: Epilepsy: a comprehensive textbook, Engel J, Pedley TA (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.775.</li><li><a class="nounderline abstract_t">Hesdorffer DC, Logroscino G, Cascino GD, Hauser WA. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology 2007; 69:73.</a></li><li><a class="nounderline abstract_t">Dodrill CB, Wilensky AJ. Intellectual impairment as an outcome of status epilepticus. Neurology 1990; 40:23.</a></li><li><a class="nounderline abstract_t">Adachi N, Kanemoto K, Muramatsu R, et al. Intellectual prognosis of status epilepticus in adult epilepsy patients: analysis with Wechsler Adult Intelligence Scale-revised. Epilepsia 2005; 46:1502.</a></li><li><a class="nounderline abstract_t">Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J Clin Neurophysiol 1995; 12:326.</a></li><li><a class="nounderline abstract_t">Chapman MG, Smith M, Hirsch NP. Status epilepticus. Anaesthesia 2001; 56:648.</a></li><li><a class="nounderline abstract_t">Donaire A, Carreno M, Gómez B, et al. Cortical laminar necrosis related to prolonged focal status epilepticus. J Neurol Neurosurg Psychiatry 2006; 77:104.</a></li><li><a class="nounderline abstract_t">Parmar H, Lim SH, Tan NC, Lim CC. Acute symptomatic seizures and hippocampus damage: DWI and MRS findings. Neurology 2006; 66:1732.</a></li><li><a class="nounderline abstract_t">Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994; 35:1104.</a></li><li><a class="nounderline abstract_t">Cockerell OC, Rothwell J, Thompson PD, et al. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain 1996; 119 ( Pt 2):393.</a></li><li><a class="nounderline abstract_t">Drislane FW, Schomer DL. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res 1994; 19:111.</a></li><li><a class="nounderline abstract_t">Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology 1988; 38:401.</a></li><li><a class="nounderline abstract_t">Simon RP, Aminoff MJ. Electrographic status epilepticus in fatal anoxic coma. Ann Neurol 1986; 20:351.</a></li><li><a class="nounderline abstract_t">Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol 1994; 35:239.</a></li><li><a class="nounderline abstract_t">Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology 1990; 40:1843.</a></li><li><a class="nounderline abstract_t">Seder DB, Sunde K, Rubertsson S, et al. Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest. Crit Care Med 2015; 43:965.</a></li><li><a class="nounderline abstract_t">Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology 2009; 72:744.</a></li><li><a class="nounderline abstract_t">Hui AC, Cheng C, Lam A, et al. Prognosis following Postanoxic Myoclonus Status epilepticus. Eur Neurol 2005; 54:10.</a></li><li><a class="nounderline abstract_t">Legriel S, Hilly-Ginoux J, Resche-Rigon M, et al. Prognostic value of electrographic postanoxic status epilepticus in comatose cardiac-arrest survivors in the therapeutic hypothermia era. Resuscitation 2013; 84:343.</a></li></ol></div><div id="topicVersionRevision">Topic 2217 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8330566" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9924914" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : It's time to revise the definition of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22528274" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines for the evaluation and management of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488380" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Status epilepticus: pathophysiology and management in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26336950" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580774" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31902646" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of status epilepticus in adults: Apples, pears, and oranges - A critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940695" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence and mortality of generalized convulsive status epilepticus in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667410" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A systematic review of the epidemiology of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185441" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Status epilepticus: epidemiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350999" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Status epilepticus: the interaction of epilepsy and acute brain disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521266" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of status epilepticus in Rochester, Minnesota, 1965-1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780085" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980736" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092915" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Status epilepticus of inflammatory etiology: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30714986" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Autoimmune seizures and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34462918" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010959" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : New-onset refractory status epilepticus (NORSE)--The potential role for immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28276060" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5925998" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epilepsia partialis continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/404996" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epilepsia partialis continua. A review of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6775582" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4205070" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nonketotic hyperglycemia and epilepsia partialis continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4205070" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nonketotic hyperglycemia and epilepsia partialis continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6829330" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Classification of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20196795" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6420145" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Some clinical and EEG aspects of benign juvenile myoclonic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16513683" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16513683" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060909" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progressive Myoclonus Epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598585" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561839" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Epilepsy in adult patients with Down syndrome: a clinical-video EEG study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25661268" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Myoclonic epilepsy in Down syndrome and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116605" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Myoclonic status epilepticus: a clinical and electroencephalographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900992" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13963212" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An electro-clinical study of generalized epileptic seizures of tonic expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6408978" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tonic status epilepticus presenting as confusional state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840875" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Is Favorable Outcome Possible After Prolonged Refractory Status Epilepticus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32943479" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : New-onset super-refractory status epilepticus: A case series of 26 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3137487" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical and electroencephalographic features of simple partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1701709" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Periodic lateralized epileptiform discharges with transitional rhythmic discharges: association with seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New-onset refractory status epilepticus with restricted DWI and neuronophagia in the pulvinar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787273" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Seizure-induced brain lesions: a wide spectrum of variably reversible MRI abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3412604" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : 'Convulsions' in basilar artery occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27333967" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bilateral Paramedian Thalamic Infarction Presenting as Status Epilepticus: A Case Report and Review of the Literatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25721014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Significant period between presentation and diagnosis in basilar artery occlusion: five cases and the lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187542" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Convulsive movements in bilateral paramedian thalamic and midbrain infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27992635" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Top of the Basilar Syndrome Presenting With Convulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32646241" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stroke-Onset Seizures During Midbrain Infarction in a Patient With Top of the Basilar Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578531" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Short-term mortality after a first episode of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31135807" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Change in Mortality of Generalized Convulsive Status Epilepticus in High-Income Countries Over Time: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7435509" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Status epilepticus. Causes, clinical features and consequences in 98 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724291" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : In-hospital mortality of generalized convulsive status epilepticus: a large US sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8112254" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Determinants of mortality in status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560020" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Epidemiology of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450988" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Status epilepticus at an urban public hospital in the 1980s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442156" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Propofol and midazolam in the treatment of refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16614020" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762449" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risk and prognostic factors of status epilepticus in the elderly: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22462650" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of comorbidities in outcome prediction after status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22462650" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Role of comorbidities in outcome prediction after status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781422" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Predictors of functional disability and mortality after status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31206357" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Causes of Death in Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972129" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Systemic complications of status epilepticus--An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16240367" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cardiac pathology in status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6538024" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Changes in plasma catecholamines after tonic-clonic seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157562" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cardiac injury in refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185436" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The biochemical basis and pathophysiology of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008655" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Functional and cognitive outcome in prolonged refractory status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890201" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Functional outcome after convulsive status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890201" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Functional outcome after convulsive status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606884" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185437" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intellectual impairment as an outcome of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16146446" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Intellectual prognosis of status epilepticus in adult epilepsy patients: analysis with Wechsler Adult Intelligence Scale-revised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560021" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pathophysiology of status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11437765" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361606" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cortical laminar necrosis related to prolonged focal status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769950" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute symptomatic seizures and hippocampus damage: DWI and MRS findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7925159" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800935" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843166" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical implications of generalized electrographic status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3347343" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767319" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Electrographic status epilepticus in fatal anoxic coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109907" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prognostic value of myoclonus status in comatose survivors of cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2123307" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The significance of myoclonic status epilepticus in postanoxic coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654176" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237704" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16015015" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prognosis following Postanoxic Myoclonus Status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23146879" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic value of electrographic postanoxic status epilepticus in comatose cardiac-arrest survivors in the therapeutic hypothermia era.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
